---
title: Integration of Transcriptomics, Proteomics and Loss-of-function Screening Reveals
  WEE1 as a Target for Combination with Dasatinib against Proneural Glioblastoma
date: '2024-09-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39332586/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240928190145&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Glioblastoma is characterized by a pronounced resistance to therapy with
  dismal prognosis. Transcriptomics classify glioblastoma into proneural (PN), mesenchymal
  (MES) and classical (CL) subtypes that show differential resistance to targeted
  therapies. The aim of this study was to provide a viable approach for identifying
  combination therapies in glioblastoma subtypes. Proteomics and phosphoproteomics
  were performed on dasatinib inhibited glioblastoma stem cells (GSCs) and complemented
  by ...
disable_comments: true
---
Glioblastoma is characterized by a pronounced resistance to therapy with dismal prognosis. Transcriptomics classify glioblastoma into proneural (PN), mesenchymal (MES) and classical (CL) subtypes that show differential resistance to targeted therapies. The aim of this study was to provide a viable approach for identifying combination therapies in glioblastoma subtypes. Proteomics and phosphoproteomics were performed on dasatinib inhibited glioblastoma stem cells (GSCs) and complemented by ...